How to Test for Hypothyroidism: A Clear Guide to Thyroid Labs

Why TSH Is the Starting Point for Every Thyroid Workup

A serum thyroid-stimulating hormone (TSH) test is the most sensitive single screening tool for detecting hypothyroidism. The American Thyroid Association (ATA) recommends TSH as the initial test because it responds to even small drops in circulating thyroid hormone before free T4 or free T3 levels fall outside their reference ranges [1]. One abnormal TSH reading can flag a problem months or years before symptoms become obvious.

TSH operates on a negative feedback loop with the hypothalamus-pituitary-thyroid axis. When the thyroid gland produces less T4 and T3, the pituitary compensates by releasing more TSH. This amplification effect makes TSH roughly 100 times more sensitive to changes in thyroid output than a direct measurement of circulating T4 [2]. A study published in the Journal of Clinical Endocrinology & Metabolism found that the log-linear relationship between TSH and free T4 means a 50% drop in free T4 can produce a 25-fold to 100-fold rise in TSH [2]. That sensitivity is precisely why TSH catches disease early.

The standard reference range sits between 0.4 and 4.5 mIU/L for most commercial assays. Some debate exists about whether the upper limit should be lowered to 2.5 mIU/L, but the ATA and the American Association of Clinical Endocrinologists (AACE) maintain 4.5 mIU/L as the diagnostic threshold in the general adult population [3]. Values above this cutoff warrant a follow-up free T4 measurement. A TSH below 0.4 mIU/L, by contrast, points toward hyperthyroidism or overtreatment.

Free T4: The Confirmatory Measurement

Free T4 testing separates overt hypothyroidism from subclinical disease. When TSH is elevated and free T4 falls below the reference range (typically 0.8 to 1.8 ng/dL), the diagnosis of overt primary hypothyroidism is confirmed [1]. If free T4 remains normal despite an elevated TSH, the patient has subclinical hypothyroidism, a condition affecting an estimated 4.3% of the U.S. adult population according to NHANES III data (N = 17,353) [4].

Free T4 measures only the unbound, biologically active fraction of thyroxine. Total T4 assays, which include protein-bound hormone, can be skewed by estrogen levels, pregnancy, oral contraceptives, and inherited variations in thyroxine-binding globulin (TBG). The 2014 ATA guidelines for hypothyroidism management specify free T4 as the preferred confirmatory test over total T4 for this reason [1].

Timing of the blood draw matters. TSH peaks overnight and begins falling after waking. A morning fasting draw between 7:00 AM and 9:00 AM produces the most reproducible TSH values. A 2019 study in Thyroid (N = 842) showed that afternoon sampling yielded TSH values up to 26% lower than early morning values in the same individuals [5]. Inconsistent draw times can create the illusion of fluctuating thyroid function when none exists.

Free T3: When and Why It Adds Value

Free T3 testing is not part of the standard hypothyroidism workup, but it provides useful data in specific clinical scenarios. The ATA does not recommend routine free T3 measurement for diagnosing primary hypothyroidism [1]. The thyroid gland produces about 20% of circulating T3 directly, while peripheral tissues convert the remaining 80% from T4 via deiodinase enzymes. In early hypothyroidism, the body upregulates this conversion to maintain T3 levels even as T4 drops, which makes free T3 a late-stage marker.

Free T3 testing becomes clinically relevant when a patient on adequate levothyroxine (normalized TSH, normal free T4) still reports persistent symptoms. The 2012 European Thyroid Association (ETA) guidelines note that roughly 5% to 10% of levothyroxine-treated patients continue to report fatigue, cognitive sluggishness, or weight gain despite biochemically normal TSH and free T4 levels [6]. In these patients, a low free T3 may prompt discussion about combination T4/T3 therapy, although the evidence supporting this approach remains mixed.

Dr. Antonio Bianco, a thyroid researcher at the University of Chicago, has stated: "Some patients on T4 monotherapy have low-normal or below-normal T3 levels, and that biochemical pattern may explain persistent symptoms in a subset of treated hypothyroid patients" [7]. This observation, from his 2019 review in The Lancet Diabetes & Endocrinology, supports the value of checking free T3 in symptomatic patients who are already on optimized T4 replacement.

TPO Antibodies: Identifying the Autoimmune Cause

Thyroid peroxidase (anti-TPO) antibody testing reveals whether Hashimoto's thyroiditis is driving the hypothyroidism. In iodine-sufficient countries, Hashimoto's accounts for approximately 90% of hypothyroidism cases [8]. Testing for TPO antibodies does not change the initial treatment decision (levothyroxine is still first-line), but it provides prognostic information that shapes long-term monitoring.

A prospective study from the Whickham Survey follow-up (N = 2,779, 20-year follow-up) demonstrated that women with elevated TSH and positive TPO antibodies had a 4.3% annual risk of progressing to overt hypothyroidism, compared to 2.6% per year in those with elevated TSH but negative antibodies [9]. That difference compounds over a decade. Knowing the antibody status helps clinicians set the right recheck interval and counsel patients about the likely trajectory of their thyroid function.

Thyroglobulin antibodies (anti-Tg) represent a second autoimmune marker. They are less specific than TPO antibodies for Hashimoto's but may be the only positive antibody in about 5% of autoimmune thyroid disease cases [8]. The ATA does not require anti-Tg testing for a standard hypothyroidism evaluation, but some clinicians add it when clinical suspicion for Hashimoto's is high and TPO antibodies come back negative.

Reading Your Results: A Practical Interpretation Framework

Interpreting thyroid labs requires matching TSH, free T4, and antibody results to clinical context. A single elevated TSH in an otherwise healthy adult does not automatically mean lifelong levothyroxine therapy. The ATA recommends repeating the TSH in 6 to 12 weeks before initiating treatment, because transient TSH elevations occur with acute illness, recovery from non-thyroidal illness (sick euthyroid syndrome), and certain medications including lithium, amiodarone, and high-dose biotin supplements [1].

The Endocrine Society's 2019 clinical practice guideline for subclinical hypothyroidism management provides clear thresholds. For TSH above 10 mIU/L with confirmed low free T4, treatment with levothyroxine is recommended in nearly all adults [10]. For subclinical hypothyroidism (TSH 4.5 to 10 mIU/L, normal free T4), the decision depends on age, symptoms, TPO antibody status, and cardiovascular risk. The guideline states: "In adults younger than 65 with TSH between 7 and 10 mIU/L, treatment is reasonable, especially if TPO antibodies are positive" [10].

Biotin supplementation deserves special attention. Doses above 5 mg per day (common in hair and nail supplements) can interfere with streptavidin-biotin immunoassays used by many commercial labs, producing falsely low TSH and falsely high free T4 readings [11]. The FDA issued a safety communication in 2017 warning that biotin interference had contributed to at least one reported death from misdiagnosed Graves' disease [11]. Patients should stop biotin supplements at least 48 hours before a thyroid blood draw.

Special Populations: Pregnancy, Older Adults, and Central Hypothyroidism

Thyroid lab interpretation shifts meaningfully across different populations. Pregnancy lowers the TSH reference range. The ATA's 2017 pregnancy guidelines recommend trimester-specific TSH cutoffs when available from the local lab, or a general upper limit of 4.0 mIU/L if population-based references are not established [12]. In the first trimester, rising hCG stimulates the thyroid directly, which naturally suppresses TSH. A TSH of 3.5 mIU/L that would be unremarkable in a non-pregnant adult may warrant free T4 testing in a woman at 8 weeks gestation.

Older adults present a different challenge. The NHANES III dataset showed that the 97.5th percentile of TSH rises with age: from 4.2 mIU/L in adults aged 20 to 29 to 7.5 mIU/L in those aged 80 and older [4]. Treating a mildly elevated TSH of 6.0 mIU/L in an 82-year-old carries risk with limited evidence of benefit. The TRUST trial (N = 737, mean age 74.4 years) found that levothyroxine treatment for subclinical hypothyroidism in adults 65 and older produced no improvement in thyroid-related symptoms or fatigue scores compared to placebo over 12 months [13].

Central (secondary) hypothyroidism, caused by pituitary or hypothalamic disease, presents a diagnostic trap. TSH may be low, normal, or only mildly elevated despite significant thyroid hormone deficiency. Free T4 is the diagnostic test of choice when central hypothyroidism is suspected, such as in patients with known pituitary tumors, prior pituitary surgery, or panhypopituitarism [1]. Relying on TSH alone will miss these cases entirely.

Which Panel Should You Request?

The right thyroid panel depends on whether this is a first-time screening or a follow-up evaluation. For initial evaluation of suspected hypothyroidism, order TSH plus free T4. This two-test panel answers the two questions that matter most: Is TSH elevated? And if so, is free T4 low (overt) or normal (subclinical)?

Add TPO antibodies if TSH is elevated on the initial draw, because antibody positivity predicts progression risk and may influence the decision to treat subclinical disease [9]. Add free T3 only if a patient on levothyroxine has persistent symptoms despite a normal TSH and free T4.

Do not order total T3, total T4, T3 uptake, or reverse T3 for a standard hypothyroidism evaluation. These tests increase cost without improving diagnostic accuracy for primary hypothyroidism. Reverse T3, in particular, has no validated role in guiding levothyroxine dosing, despite widespread claims in direct-to-consumer wellness marketing [14]. The ATA and the Endocrine Society have not included reverse T3 in any hypothyroidism diagnostic or management guideline.

For patients already on levothyroxine, a TSH alone is sufficient for routine dose monitoring, drawn 6 to 8 weeks after any dose change. The blood draw should occur before the morning levothyroxine dose, or at minimum 4 hours after taking the medication, to avoid a transient free T4 spike that could confuse interpretation [1].

What to Do After You Get Your Results

An abnormal thyroid panel is not the end of the diagnostic process. It is the beginning. Confirm an elevated TSH with a repeat draw before starting treatment, unless TSH exceeds 10 mIU/L with clear symptoms [10]. Obtain TPO antibodies if not yet checked. Review the medication list for thyroid-interfering drugs (lithium, amiodarone, immune checkpoint inhibitors, tyrosine kinase inhibitors). Check for non-thyroidal illness if the patient is acutely hospitalized.

Once levothyroxine therapy is initiated, the target TSH for most adults is 0.5 to 2.5 mIU/L, with the ATA recommending the lower half of the reference range rather than simply "normal" [1]. Starting dose for overt hypothyroidism is typically 1.6 mcg/kg/day of levothyroxine in young, otherwise healthy adults. Older adults and those with coronary artery disease start lower, at 25 to 50 mcg/day, with dose titration every 6 to 8 weeks [1].

Patients diagnosed with subclinical hypothyroidism who do not initiate treatment should have TSH rechecked every 6 to 12 months. Annual monitoring is especially important when TPO antibodies are positive, given the 4.3% per year progression rate documented in the Whickham Survey [9].